Trial Profile
Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Ibrutinib (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 05 Oct 2022 Status changed from active, no longer recruiting to completed.
- 11 Jan 2022 Planned End Date changed from 1 Sep 2021 to 1 Jul 2022.
- 06 Apr 2021 Planned End Date changed from 1 Nov 2020 to 1 Sep 2021.